CEO and Co-Founder, BioNTech
Appears in 1 story
Leading BioNTech's cancer vaccine portfolio expansion
Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer, pointing to a mechanism that could make therapeutic cancer vaccines work reliably.
Updated Jan 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
